Univariate and multivariate analyses of predictors of disease-specific survival in the entire cohort (n=281)
| Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| Variable | No. | Median (months) | 3 year s (%) | 5 years (%) | p Value | HR | 95% CI | p Value |
| Gender | ||||||||
| Male | 163 | NR | 92.3 | 83.9 | 1 | – | – | |
| Female | 118 | NR | 96.5 | 96.5 | 0.043 | 0.472 | 0.123 to 1.806 | 0.273 |
| Age | ||||||||
| ≤70 | 146 | NR | 96.8 | 94.5 | 1 | – | – | |
| >70 | 135 | 141 | 92.6 | 84.1 | <0.0001 | 10.279 | 2.171 to 48.66 | 0.003 |
| ACE 27 score | ||||||||
| ≤2 | 208 | NR | 98.4 | 97.3 | 1 | – | – | |
| >3 | 73 | NR | 83.1 | 71.4 | <0.0001 | 3.639 | 0.748 to 17.70 | 0.110 |
| Presence of diabetes | ||||||||
| No | 204 | NR | 96.1 | 93.3 | 1 | – | – | |
| Yes | 77 | NR | 89.4 | 81.9 | 0.038 | 0.704 | 0.172 to 2.884 | 0.626 |
| Previous neoplasm | ||||||||
| No | 196 | NR | 95.4 | 91.2 | ||||
| Yes | 85 | NR | 91.9 | 87.5 | 0.105 | |||
| Family history of PDA | ||||||||
| No | 263 | NR | 94.5 | 90.6 | ||||
| Yes | 13 | NR | 91.7 | 81.5 | 0.424 | |||
| IPMN-related symptoms | ||||||||
| No | 213 | NR | 97 | 95.1 | 1 | – | – | |
| Yes | 68 | NR | 85.8 | 74.4 | <0.0001 | 2.263 | 0.556 to 9.210 | 0.254 |
| IPMN type | ||||||||
| BD IPMN | 159 | NR | 98.5 | 97.1 | 1 | – | – | |
| MD/mixed IPMN | 122 | NR | 89.8 | 81.2 | <0.0001 | 2.025 | 0.489 to 8.391 | 0.331 |
| Lesions distribution | ||||||||
| Unifocal | 139 | NR | 95.1 | 89.7 | ||||
| Multifocal | 138 | NR | 94.1 | 91.1 | 0.902 | |||
| Non-enhanced nodules | ||||||||
| No | 249 | NR | 94.5 | 90.5 | ||||
| Yes | 32 | NR | 92.5 | 85.9 | 0.433 | |||
| Cyst >30 mm | ||||||||
| No | 101 | NR | 93.2 | 85.9 | ||||
| Yes | 180 | NR | 94.9 | 92.8 | 0.145 | |||
| Atypical cytology | ||||||||
| No | 270 | NR | 95.2 | 90.9 | 1 | – | – | |
| Yes | 11 | NR | 72.7 | 72.7 | <0.0001 | 11.576 | 1.641 to 81.65 | 0.014 |
| IPMN-related features | ||||||||
| Worrisome feature | 231 | NR | 98.9 | 96.2 | 1 | – | – | |
| High-risk stigmata | 50 | 108 | 73 | 62.2 | <0.0001 | 1.839 | 0.185 to 18.33 | 0.603 |
| Malignant cytology | ||||||||
| No | 276 | NR | 95.4 | 91.7 | 1 | – | – | |
| Yes | 5 | 29 | 40.0 | 0 | <0.0001 | 21.502 | 2.94 to 156.72 | 0.002 |
| Jaundice | ||||||||
| No | 273 | NR | 96.5 | 92.2 | 1 | – | – | |
| Yes | 8 | 14 | 18.8 | 18.8 | <0.0001 | 28.429 | 3.73 to 216.36 | 0.001 |
| Vascularised nodules | ||||||||
| No | 259 | NR | 96.3 | 92.6 | 1 | – | – | |
| Yes | 22 | NR | 70.6 | 58.8 | <0.0001 | 0.961 | 0.171 to 5.397 | 0.964 |
| MPD >10 mm | ||||||||
| No | 250 | NR | 98.1 | 95.5 | 1 | – | – | |
| Yes | 31 | 55 | 64.4 | 48.6 | <0.0001 | 1.740 | 0.165 to 18.40 | 0.645 |
| Surgery during FU | ||||||||
| No | 243 | NR | 93.9 | 89.8 | ||||
| Yes | 38 | NR | 97.0 | 91.9 | 0.295 | |||
| Cyst size >50 mm | ||||||||
| No | 246 | NR | 95.3 | 92.1 | 1 | – | – | |
| Yes | 15 | NR | 79.0 | 79.0 | 0.026 | 0.354 | 0.035 to 3.533 | 0.376 |
| MPD >15 mm | ||||||||
| No | 273 | NR | 96.5 | 92.1 | 1 | – | ||
| Yes | 8 | 15 | 25 | 25 | <0.0001 | 9.640 | 1.448 to 64.18 | 0.019 |
ACE, Adult Comorbidities Evaluation; BD, branch duct; FU, follow-up; IPMNs, intraductal papillary mucinous neoplasms; MD, main duct; MPD, main pancreatic duct; NR, not reached; PDA, pancreatic ductal adenocarcinoma.